Revolution Medicines won FDA approval for daraxonrasib (Rasonque), a once-daily oral pan-RAS inhibitor, in advanced pancreatic ductal adenocarcinoma. The agency’s decision covers patients who have progressed after chemotherapy, setting a new treatment line for a cancer with limited options and poor outcomes. Analysts and clinicians pointed to the phase 3 results as practice-changing for genetically defined disease. In the trial cited in the coverage, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy across the overall population. The speed of the regulatory outcome and the drug’s mechanism—targeting an oncogenic driver rather than broad cytotoxic therapy—raise the prospect of more RAS-aligned strategies entering clinical practice as additional biomarker-linked approaches mature.